SYHX2008 clinical trials
Also written SYHX2008.
How each study uses SYHX2008 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SYHX2008 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test SYHX2008.
- Aug 2027A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)Phase 2 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Studies
Open first, then newest update. How each study uses SYHX2008 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With AcromegalyNot yet recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07623824Written as SYHX2008
- A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)RecruitingPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06505395Written as SYHX2008 injection
- A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With AcromegalyCompletedPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07814651Written as SYHX2008
- A Single-dose Study of Octreotide Injection in Healthy Adult SubjectsCompletedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05761431Written as SYHX2008 injection